Filtered By:
Specialty: Cardiology
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 1444 results found since Jan 2013.
Thrombotic Risk Stratification and Intensive Statin Therapy for Secondary Prevention of Coronary Artery Disease - Insights From the REAL-CAD Study
CONCLUSIONS: High-dose pitavastatin therapy compared with low-dose pitavastatin therapy was associated with a trend toward lowering the risk for cardiovascular events irrespective of the thrombotic risk in patients with CCS.PMID:35934778 | DOI:10.1253/circj.CJ-22-0315
Source: Circulation Journal - August 7, 2022 Category: Cardiology Authors: Masahiro Natsuaki Takeshi Morimoto Satoshi Iimuro Retsu Fujita Hiroshi Iwata Katsumi Miyauchi Teruo Inoue Yoshihisa Nakagawa Yosuke Nishihata Hiroyuki Daida Yukio Ozaki Satoru Suwa Ichiro Sakuma Yutaka Furukawa Hiroki Shiomi Hirotoshi Watanabe Kyohei Yama Source Type: research
Lipid Lowering Therapy: An Era Beyond Statins
Curr Probl Cardiol. 2022 Jul 30:101342. doi: 10.1016/j.cpcardiol.2022.101342. Online ahead of print.ABSTRACTDyslipidemia, specifically elevated LDL cholesterol levels, causes atherosclerotic cardiovascular disease (ASCVD) and increases the risk of myocardial infarction and stroke. Statins, a class of drugs that exert their effects by inhibiting HMG-CoA reductase, a key enzyme in the synthesis of cholesterol, have been the mainstay of therapy for the primary prevention of cardiovascular disease and lipids reduction. Statins are associated with side effects, most commonly myopathy and myalgias, despite their proven efficacy....
Source: Atherosclerosis - August 2, 2022 Category: Cardiology Authors: Toufik Abdul-Rahman Syed Muhammad Awais Bukhari Emiliano Cantu Herrera Wireko Andrew Awuah Jannel Lawrence Heloisa de Andrade Neal Patel Rohan Shah Raheel Shaikh Camilo Andr és Avendaño Capriles Sebahat Ulusan Shahzaib Ahmad Anna Corriero Adriana C Mare Source Type: research
The Multi-Ethnic Study of Atherosclerosis-Calcium Score Improves Statin Treatment Allocation in Asymptomatic Adults
CONCLUSION: In asymptomatic subjects, the MESA-C score improves allocation to statin treatment and CV risk discrimination, while both scores are essential for more precise survival estimations.PMID:35911540 | PMC:PMC9334900 | DOI:10.3389/fcvm.2022.855390
Source: Atherosclerosis - August 1, 2022 Category: Cardiology Authors: Gadi Shlomai Joseph Shemesh Shlomo Segev Nira Koren-Morag Ehud Grossman Source Type: research
BMJ Rapid Recommendations on use of proprotein convertase subtilisin/kexin 9 inhibitors and ezetimibe to reduce cardiovascular risk
The new BMJ Rapid Recommendations addressed the following question: should we add another lipid-lowering drug in adults with low-density lipoprotein-cholesterol (LDL-C) over 1.8 mmol/L using a maximal dose of statins or intolerant to statins?1 Why is this question important? Both proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and ezetimibe have been shown to reduce LDL-C by approximately 60% and approximately 20%, respectively, and correspondingly may reduce major adverse cardiovascular events (MACE), including all-cause death, cardiovascular death, myocardial infarction (MI) and stroke. However, the bene...
Source: Heart - July 27, 2022 Category: Cardiology Authors: White, H. D. Tags: Editorials Source Type: research
Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome
This study was a prospective, randomized controlled study. A total of 136 patients with extremely high-risk ACS with LDL-C ≥ 3.0 mmol/L after percutaneous coronary intervention (PCI) treatment were randomly assigned 1:1 to the control group (atorvastatin 40 mg/day and ezetimibe 10 mg/day) or the evolocumab group (evolocumab 140 mg every 2 weeks combined with atorvastatin 40 mg/day and ezetimibe 10 mg/day). We compared the blood lipid profiles, major adverse cardiovascular events (MACEs), and adverse reactions. MACEs included cardiogenic death, nonfatal myocardial infarction, nonfatal stroke, and readmission due to angina...
Source: International Heart Journal - July 13, 2022 Category: Cardiology Authors: Yan Hao Yu-Lin Yang Yong-Chao Wang Jian Li Source Type: research
